Loading...
Header Logo
Keywords
Last Name
Institution

ONDREJ HAVRANEK

TitleInstructor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019 Jun 19; 11(497). PMID: 31217338.
      View in: PubMed
    2. Kleiblova P, Stolarova L, Krizova K, Lhota F, Hojny J, Zemankova P, Havranek O, Vocka M, Cerna M, Lhotova K, Borecka M, Janatova M, Soukupova J, Sevcik J, Zimovjanova M, Kotlas J, Panczak A, Vesela K, Cervenkova J, Schneiderova M, Burocziova M, Burdova K, Stranecky V, Foretova L, Machackova E, Tavandzis S, Kmoch S, Macurek L, Kleibl Z. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019 Oct 01; 145(7):1782-1797. PMID: 31050813.
      View in: PubMed
    3. Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. Clin Cancer Res. 2019 Jul 15; 25(14):4455-4465. PMID: 31004002.
      View in: PubMed
    4. Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 12; 15(12):1692-1703. PMID: 28835371.
      View in: PubMed
    5. Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017 08 24; 130(8):995-1006. PMID: 28646116.
      View in: PubMed
    6. Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017 02; 102(2):373-380. PMID: 27742770.
      View in: PubMed
    7. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 06; 30(6):1246-54. PMID: 26847027.
      View in: PubMed
    8. Havranek O, Kleiblova P, Hojny J, Lhota F, Soucek P, Trneny M, Kleibl Z. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma. PLoS One. 2015; 10(10):e0140819. PMID: 26506619.
      View in: PubMed
    9. Cvek J, Feltl D, Hajek J, Jackaninova J, Ruzickova K, Havranek O, Dvorackova J, Dobes P. Is there an intermediate-risk non-seminoma? long-term treatment results from a single center. J BUON. 2014 Jul-Sep; 19(3):775-9. PMID: 25261666.
      View in: PubMed
    10. Havranek O, Spacek M, Hubacek P, Mocikova H, Benesova K, Soucek P, Trneny M, Kleibl Z. No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma. Leuk Res. 2011 Aug; 35(8):1117-9. PMID: 21546086.
      View in: PubMed
    11. Havranek O, Spacek M, Hubacek P, Mocikova H, Markova J, Trneny M, Kleibl Z. Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma. Neoplasma. 2011; 58(5):392-5. PMID: 21744992.
      View in: PubMed
    12. Mohelnikova-Duchonova B, Havranek O, Hlavata I, Foretova L, Kleibl Z, Pohlreich P, Soucek P. CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer. Cancer Epidemiol. 2010 Oct; 34(5):656-8. PMID: 20643596.
      View in: PubMed
    13. Kleibl Z, Havranek O, Kormunda S, Novotny J, Foretova L, Machackova E, Soukupova J, Janatova M, Tavandzis S, Pohlreich P. The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development. J Cancer Res Clin Oncol. 2011 Feb; 137(2):331-8. PMID: 20422428.
      View in: PubMed
    14. Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, Soucek P. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer. 2009 Mar; 45(4):618-24. PMID: 18996005.
      View in: PubMed
    15. Kleibl Z, Havranek O, Novotny J, Kleiblova P, Soucek P, Pohlreich P. Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations. Breast Cancer Res Treat. 2008 Nov; 112(1):159-64. PMID: 18058223.
      View in: PubMed
    16. Kleibl Z, Havranek O, Prokopcova J. Rapid detection of CAA/CAG repeat polymorphism in the AIB1 gene using DHPLC. J Biochem Biophys Methods. 2007 Apr 10; 70(3):511-3. PMID: 17234271.
      View in: PubMed
    17. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia.
    18. Analýza mutace c.1100delC genu CHEK2 v populaci pacientů se sporadickým karcinomem kolorekta a familiární adenomatózní polypózou. Klinicka Onkologie. 20:224-226.
    19. Association of germline CHEK2 gene variants with risk and prognosis of Non-Hodgkin Lymphoma. PLoS One. 10.
    HAVRANEK's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description